The global FGF-2 Inhibitors market is projected to grow from US$ 2143 million in 2024 to US$ 3180.2 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period.

FGF-2 Inhibitors Market

Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm.

Market Analysis and Insights: Global FGF-2 Inhibitors Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for FGF-2 Inhibitors market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of FGF-2 Inhibitors, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for FGF-2 Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the FGF-2 Inhibitors revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global FGF-2 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for FGF-2 Inhibitors revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of FGF-2 Inhibitors Market Report

Report Metric	Details
Report Name	FGF-2 Inhibitors Market
Accounted market size in 2024	US$ 2143 million
Forecasted market size in 2030	US$ 3180.2 million
CAGR	6.8
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	ASP-5878 AZD-4547 BAY-1163877 CPL-043 Debio-1347 EDP-317 Others
Segment by Application	Clinic Hospital Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of FGF-2 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of FGF-2 Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, FGF-2 Inhibitors revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is FGF-2 Inhibitors Market growing?

Ans: The FGF-2 Inhibitors Market witnessing a CAGR of 6.8 during the forecast period 2024-2030.

What is the FGF-2 Inhibitors Market size in 2030?

Ans: The FGF-2 Inhibitors Market size in 2030 will be US$ 3180.2 million.

Who are the main players in the FGF-2 Inhibitors Market report?

Ans: The main players in the FGF-2 Inhibitors Market are Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research

What are the Application segmentation covered in the FGF-2 Inhibitors Market report?

Ans: The Applications covered in the FGF-2 Inhibitors Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the FGF-2 Inhibitors Market report?

Ans: The Types covered in the FGF-2 Inhibitors Market report are ASP-5878, AZD-4547, BAY-1163877, CPL-043, Debio-1347, EDP-317, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global FGF-2 Inhibitors Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 ASP-5878

1.2.3 AZD-4547

1.2.4 BAY-1163877

1.2.5 CPL-043

1.2.6 Debio-1347

1.2.7 EDP-317

1.2.8 Others

1.3 Market by Application

1.3.1 Global FGF-2 Inhibitors Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global FGF-2 Inhibitors Market Perspective (2019-2030)

2.2 Global FGF-2 Inhibitors Growth Trends by Region

2.2.1 FGF-2 Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 FGF-2 Inhibitors Historic Market Size by Region (2019-2024)

2.2.3 FGF-2 Inhibitors Forecasted Market Size by Region (2025-2030)

2.3 FGF-2 Inhibitors Market Dynamics

2.3.1 FGF-2 Inhibitors Industry Trends

2.3.2 FGF-2 Inhibitors Market Drivers

2.3.3 FGF-2 Inhibitors Market Challenges

2.3.4 FGF-2 Inhibitors Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue FGF-2 Inhibitors by Players

3.1.1 Global FGF-2 Inhibitors Revenue by Players (2019-2024)

3.1.2 Global FGF-2 Inhibitors Revenue Market Share by Players (2019-2024)

3.2 Global FGF-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of FGF-2 Inhibitors, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global FGF-2 Inhibitors Market Concentration Ratio

3.4.1 Global FGF-2 Inhibitors Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by FGF-2 Inhibitors Revenue in 2023

3.5 Global Key Players of FGF-2 Inhibitors Head office and Area Served

3.6 Global Key Players of FGF-2 Inhibitors, Product and Application

3.7 Global Key Players of FGF-2 Inhibitors, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 FGF-2 Inhibitors Breakdown Data by Type

4.1 Global FGF-2 Inhibitors Historic Market Size by Type (2019-2024)

4.2 Global FGF-2 Inhibitors Forecasted Market Size by Type (2025-2030)

5 FGF-2 Inhibitors Breakdown Data by Application

5.1 Global FGF-2 Inhibitors Historic Market Size by Application (2019-2024)

5.2 Global FGF-2 Inhibitors Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America FGF-2 Inhibitors Market Size (2019-2030)

6.2 North America FGF-2 Inhibitors Market Size by Type

6.2.1 North America FGF-2 Inhibitors Market Size by Type (2019-2024)

6.2.2 North America FGF-2 Inhibitors Market Size by Type (2025-2030)

6.2.3 North America FGF-2 Inhibitors Market Share by Type (2019-2030)

6.3 North America FGF-2 Inhibitors Market Size by Application

6.3.1 North America FGF-2 Inhibitors Market Size by Application (2019-2024)

6.3.2 North America FGF-2 Inhibitors Market Size by Application (2025-2030)

6.3.3 North America FGF-2 Inhibitors Market Share by Application (2019-2030)

6.4 North America FGF-2 Inhibitors Market Size by Country

6.4.1 North America FGF-2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America FGF-2 Inhibitors Market Size by Country (2019-2024)

6.4.3 North America FGF-2 Inhibitors Market Size by Country (2025-2030)

6.4.4 United States

6.4.5 Canada

7 Europe

7.1 Europe FGF-2 Inhibitors Market Size (2019-2030)

7.2 Europe FGF-2 Inhibitors Market Size by Type

7.2.1 Europe FGF-2 Inhibitors Market Size by Type (2019-2024)

7.2.2 Europe FGF-2 Inhibitors Market Size by Type (2025-2030)

7.2.3 Europe FGF-2 Inhibitors Market Share by Type (2019-2030)

7.3 Europe FGF-2 Inhibitors Market Size by Application

7.3.1 Europe FGF-2 Inhibitors Market Size by Application (2019-2024)

7.3.2 Europe FGF-2 Inhibitors Market Size by Application (2025-2030)

7.3.3 Europe FGF-2 Inhibitors Market Share by Application (2019-2030)

7.4 Europe FGF-2 Inhibitors Market Size by Country

7.4.1 Europe FGF-2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe FGF-2 Inhibitors Market Size by Country (2019-2024)

7.4.3 Europe FGF-2 Inhibitors Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China FGF-2 Inhibitors Market Size (2019-2030)

8.2 China FGF-2 Inhibitors Market Size by Type

8.2.1 China FGF-2 Inhibitors Market Size by Type (2019-2024)

8.2.2 China FGF-2 Inhibitors Market Size by Type (2025-2030)

8.2.3 China FGF-2 Inhibitors Market Share by Type (2019-2030)

8.3 China FGF-2 Inhibitors Market Size by Application

8.3.1 China FGF-2 Inhibitors Market Size by Application (2019-2024)

8.3.2 China FGF-2 Inhibitors Market Size by Application (2025-2030)

8.3.3 China FGF-2 Inhibitors Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia FGF-2 Inhibitors Market Size (2019-2030)

9.2 Asia FGF-2 Inhibitors Market Size by Type

9.2.1 Asia FGF-2 Inhibitors Market Size by Type (2019-2024)

9.2.2 Asia FGF-2 Inhibitors Market Size by Type (2025-2030)

9.2.3 Asia FGF-2 Inhibitors Market Share by Type (2019-2030)

9.3 Asia FGF-2 Inhibitors Market Size by Application

9.3.1 Asia FGF-2 Inhibitors Market Size by Application (2019-2024)

9.3.2 Asia FGF-2 Inhibitors Market Size by Application (2025-2030)

9.3.3 Asia FGF-2 Inhibitors Market Share by Application (2019-2030)

9.4 Asia FGF-2 Inhibitors Market Size by Region

9.4.1 Asia FGF-2 Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia FGF-2 Inhibitors Market Size by Region (2019-2024)

9.4.3 Asia FGF-2 Inhibitors Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Type

10.2.1 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Application

10.3.1 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country

10.4.1 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Advenchen Laboratories

11.1.1 Advenchen Laboratories Company Details

11.1.2 Advenchen Laboratories Business Overview

11.1.3 Advenchen Laboratories FGF-2 Inhibitors Introduction

11.1.4 Advenchen Laboratories Revenue in FGF-2 Inhibitors Business (2019-2024)

11.1.5 Advenchen Laboratories Recent Developments

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen FGF-2 Inhibitors Introduction

11.2.4 Amgen Revenue in FGF-2 Inhibitors Business (2019-2024)

11.2.5 Amgen Recent Developments

11.3 ArQule

11.3.1 ArQule Company Details

11.3.2 ArQule Business Overview

11.3.3 ArQule FGF-2 Inhibitors Introduction

11.3.4 ArQule Revenue in FGF-2 Inhibitors Business (2019-2024)

11.3.5 ArQule Recent Developments

11.4 Santa Cruz Biotechnology

11.4.1 Santa Cruz Biotechnology Company Details

11.4.2 Santa Cruz Biotechnology Business Overview

11.4.3 Santa Cruz Biotechnology FGF-2 Inhibitors Introduction

11.4.4 Santa Cruz Biotechnology Revenue in FGF-2 Inhibitors Business (2019-2024)

11.4.5 Santa Cruz Biotechnology Recent Developments

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca FGF-2 Inhibitors Introduction

11.5.4 AstraZeneca Revenue in FGF-2 Inhibitors Business (2019-2024)

11.5.5 AstraZeneca Recent Developments

11.6 AVEO Pharmaceuticals

11.6.1 AVEO Pharmaceuticals Company Details

11.6.2 AVEO Pharmaceuticals Business Overview

11.6.3 AVEO Pharmaceuticals FGF-2 Inhibitors Introduction

11.6.4 AVEO Pharmaceuticals Revenue in FGF-2 Inhibitors Business (2019-2024)

11.6.5 AVEO Pharmaceuticals Recent Developments

11.7 Batu Biologics

11.7.1 Batu Biologics Company Details

11.7.2 Batu Biologics Business Overview

11.7.3 Batu Biologics FGF-2 Inhibitors Introduction

11.7.4 Batu Biologics Revenue in FGF-2 Inhibitors Business (2019-2024)

11.7.5 Batu Biologics Recent Developments

11.8 Boehringer Ingelheim

11.8.1 Boehringer Ingelheim Company Details

11.8.2 Boehringer Ingelheim Business Overview

11.8.3 Boehringer Ingelheim FGF-2 Inhibitors Introduction

11.8.4 Boehringer Ingelheim Revenue in FGF-2 Inhibitors Business (2019-2024)

11.8.5 Boehringer Ingelheim Recent Developments

11.9 Bristol-Myers Squibb Company

11.9.1 Bristol-Myers Squibb Company Company Details

11.9.2 Bristol-Myers Squibb Company Business Overview

11.9.3 Bristol-Myers Squibb Company FGF-2 Inhibitors Introduction

11.9.4 Bristol-Myers Squibb Company Revenue in FGF-2 Inhibitors Business (2019-2024)

11.9.5 Bristol-Myers Squibb Company Recent Developments

11.10 Celon Pharma

11.10.1 Celon Pharma Company Details

11.10.2 Celon Pharma Business Overview

11.10.3 Celon Pharma FGF-2 Inhibitors Introduction

11.10.4 Celon Pharma Revenue in FGF-2 Inhibitors Business (2019-2024)

11.10.5 Celon Pharma Recent Developments

11.11 Debiopharm International

11.11.1 Debiopharm International Company Details

11.11.2 Debiopharm International Business Overview

11.11.3 Debiopharm International FGF-2 Inhibitors Introduction

11.11.4 Debiopharm International Revenue in FGF-2 Inhibitors Business (2019-2024)

11.11.5 Debiopharm International Recent Developments

11.12 Eddingpharm

11.12.1 Eddingpharm Company Details

11.12.2 Eddingpharm Business Overview

11.12.3 Eddingpharm FGF-2 Inhibitors Introduction

11.12.4 Eddingpharm Revenue in FGF-2 Inhibitors Business (2019-2024)

11.12.5 Eddingpharm Recent Developments

11.13 Eisai

11.13.1 Eisai Company Details

11.13.2 Eisai Business Overview

11.13.3 Eisai FGF-2 Inhibitors Introduction

11.13.4 Eisai Revenue in FGF-2 Inhibitors Business (2019-2024)

11.13.5 Eisai Recent Developments

11.14 Eli Lilly and Company

11.14.1 Eli Lilly and Company Company Details

11.14.2 Eli Lilly and Company Business Overview

11.14.3 Eli Lilly and Company FGF-2 Inhibitors Introduction

11.14.4 Eli Lilly and Company Revenue in FGF-2 Inhibitors Business (2019-2024)

11.14.5 Eli Lilly and Company Recent Developments

11.15 Hutchison MediPharma

11.15.1 Hutchison MediPharma Company Details

11.15.2 Hutchison MediPharma Business Overview

11.15.3 Hutchison MediPharma FGF-2 Inhibitors Introduction

11.15.4 Hutchison MediPharma Revenue in FGF-2 Inhibitors Business (2019-2024)

11.15.5 Hutchison MediPharma Recent Developments

11.16 Novartis

11.16.1 Novartis Company Details

11.16.2 Novartis Business Overview

11.16.3 Novartis FGF-2 Inhibitors Introduction

11.16.4 Novartis Revenue in FGF-2 Inhibitors Business (2019-2024)

11.16.5 Novartis Recent Developments

11.17 Principia Biopharma

11.17.1 Principia Biopharma Company Details

11.17.2 Principia Biopharma Business Overview

11.17.3 Principia Biopharma FGF-2 Inhibitors Introduction

11.17.4 Principia Biopharma Revenue in FGF-2 Inhibitors Business (2019-2024)

11.17.5 Principia Biopharma Recent Developments

11.18 Vichem Chemie Research

11.18.1 Vichem Chemie Research Company Details

11.18.2 Vichem Chemie Research Business Overview

11.18.3 Vichem Chemie Research FGF-2 Inhibitors Introduction

11.18.4 Vichem Chemie Research Revenue in FGF-2 Inhibitors Business (2019-2024)

11.18.5 Vichem Chemie Research Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Advenchen Laboratories

Amgen Inc

ArQule Inc

Santa Cruz Biotechnology

Bristol Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eisai Co Ltd

Eli Lilly and Company

Hutchison MediPharma

Novartis

Principia Biopharma

Vichem Chemie Research

List of Tables

Table 1. Global FGF-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of ASP-5878

Table 3. Key Players of AZD-4547

Table 4. Key Players of BAY-1163877

Table 5. Key Players of CPL-043

Table 6. Key Players of Debio-1347

Table 7. Key Players of EDP-317

Table 8. Key Players of Others

Table 9. Global FGF-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 10. Global FGF-2 Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 11. Global FGF-2 Inhibitors Market Size by Region (2019-2024) & (US$ Million)

Table 12. Global FGF-2 Inhibitors Market Share by Region (2019-2024)

Table 13. Global FGF-2 Inhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 14. Global FGF-2 Inhibitors Market Share by Region (2025-2030)

Table 15. FGF-2 Inhibitors Market Trends

Table 16. FGF-2 Inhibitors Market Drivers

Table 17. FGF-2 Inhibitors Market Challenges

Table 18. FGF-2 Inhibitors Market Restraints

Table 19. Global FGF-2 Inhibitors Revenue by Players (2019-2024) & (US$ Million)

Table 20. Global FGF-2 Inhibitors Revenue Share by Players (2019-2024)

Table 21. Global Top FGF-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in FGF-2 Inhibitors as of 2023)

Table 22. Global FGF-2 Inhibitors Industry Ranking 2022 VS 2023 VS 2024

Table 23. Global 5 Largest Players Market Share by FGF-2 Inhibitors Revenue (CR5 and HHI) & (2019-2024)

Table 24. Global Key Players of FGF-2 Inhibitors, Headquarters and Area Served

Table 25. Global Key Players of FGF-2 Inhibitors, Product and Application

Table 26. Global Key Players of FGF-2 Inhibitors, Product and Application

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 29. Global FGF-2 Inhibitors Revenue Market Share by Type (2019-2024)

Table 30. Global FGF-2 Inhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 31. Global FGF-2 Inhibitors Revenue Market Share by Type (2025-2030)

Table 32. Global FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 33. Global FGF-2 Inhibitors Revenue Share by Application (2019-2024)

Table 34. Global FGF-2 Inhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 35. Global FGF-2 Inhibitors Revenue Share by Application (2025-2030)

Table 36. North America FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 37. North America FGF-2 Inhibitors Market Size by Type (2025-2030) & (US$ Million)

Table 38. North America FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 39. North America FGF-2 Inhibitors Market Size by Application (2025-2030) & (US$ Million)

Table 40. North America FGF-2 Inhibitors Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. North America FGF-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)

Table 42. North America FGF-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)

Table 43. Europe FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 44. Europe FGF-2 Inhibitors Market Size by Type (2025-2030) & (US$ Million)

Table 45. Europe FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 46. Europe FGF-2 Inhibitors Market Size by Application (2025-2030) & (US$ Million)

Table 47. Europe FGF-2 Inhibitors Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Europe FGF-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)

Table 49. Europe FGF-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)

Table 50. China FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 51. China FGF-2 Inhibitors Market Size by Type (2025-2030) & (US$ Million)

Table 52. China FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 53. China FGF-2 Inhibitors Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 55. Asia FGF-2 Inhibitors Market Size by Type (2025-2030) & (US$ Million)

Table 56. Asia FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 57. Asia FGF-2 Inhibitors Market Size by Application (2025-2030) & (US$ Million)

Table 58. Asia FGF-2 Inhibitors Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 59. Asia FGF-2 Inhibitors Market Size by Region (2019-2024) & (US$ Million)

Table 60. Asia FGF-2 Inhibitors Market Size by Region (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Type (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Type (2025-2030) & (US$ Million)

Table 63. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Application (2019-2024) & (US$ Million)

Table 64. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Application (2025-2030) & (US$ Million)

Table 65. Middle East, Africa, and Latin America FGF-2 Inhibitors Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 66. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country (2019-2024) & (US$ Million)

Table 67. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size by Country (2025-2030) & (US$ Million)

Table 68. Advenchen Laboratories Company Details

Table 69. Advenchen Laboratories Business Overview

Table 70. Advenchen Laboratories FGF-2 Inhibitors Product

Table 71. Advenchen Laboratories Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 72. Advenchen Laboratories Recent Developments

Table 73. Amgen Company Details

Table 74. Amgen Business Overview

Table 75. Amgen FGF-2 Inhibitors Product

Table 76. Amgen Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 77. Amgen Recent Developments

Table 78. ArQule Company Details

Table 79. ArQule Business Overview

Table 80. ArQule FGF-2 Inhibitors Product

Table 81. ArQule Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 82. ArQule Recent Developments

Table 83. Santa Cruz Biotechnology Company Details

Table 84. Santa Cruz Biotechnology Business Overview

Table 85. Santa Cruz Biotechnology FGF-2 Inhibitors Product

Table 86. Santa Cruz Biotechnology Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 87. Santa Cruz Biotechnology Recent Developments

Table 88. AstraZeneca Company Details

Table 89. AstraZeneca Business Overview

Table 90. AstraZeneca FGF-2 Inhibitors Product

Table 91. AstraZeneca Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 92. AstraZeneca Recent Developments

Table 93. AVEO Pharmaceuticals Company Details

Table 94. AVEO Pharmaceuticals Business Overview

Table 95. AVEO Pharmaceuticals FGF-2 Inhibitors Product

Table 96. AVEO Pharmaceuticals Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 97. AVEO Pharmaceuticals Recent Developments

Table 98. Batu Biologics Company Details

Table 99. Batu Biologics Business Overview

Table 100. Batu Biologics FGF-2 Inhibitors Product

Table 101. Batu Biologics Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 102. Batu Biologics Recent Developments

Table 103. Boehringer Ingelheim Company Details

Table 104. Boehringer Ingelheim Business Overview

Table 105. Boehringer Ingelheim FGF-2 Inhibitors Product

Table 106. Boehringer Ingelheim Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 107. Boehringer Ingelheim Recent Developments

Table 108. Bristol-Myers Squibb Company Company Details

Table 109. Bristol-Myers Squibb Company Business Overview

Table 110. Bristol-Myers Squibb Company FGF-2 Inhibitors Product

Table 111. Bristol-Myers Squibb Company Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 112. Bristol-Myers Squibb Company Recent Developments

Table 113. Celon Pharma Company Details

Table 114. Celon Pharma Business Overview

Table 115. Celon Pharma FGF-2 Inhibitors Product

Table 116. Celon Pharma Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 117. Celon Pharma Recent Developments

Table 118. Debiopharm International Company Details

Table 119. Debiopharm International Business Overview

Table 120. Debiopharm International FGF-2 Inhibitors Product

Table 121. Debiopharm International Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 122. Debiopharm International Recent Developments

Table 123. Eddingpharm Company Details

Table 124. Eddingpharm Business Overview

Table 125. Eddingpharm FGF-2 Inhibitors Product

Table 126. Eddingpharm Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 127. Eddingpharm Recent Developments

Table 128. Eisai Company Details

Table 129. Eisai Business Overview

Table 130. Eisai FGF-2 Inhibitors Product

Table 131. Eisai Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 132. Eisai Recent Developments

Table 133. Eli Lilly and Company Company Details

Table 134. Eli Lilly and Company Business Overview

Table 135. Eli Lilly and Company FGF-2 Inhibitors Product

Table 136. Eli Lilly and Company Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 137. Eli Lilly and Company Recent Developments

Table 138. Hutchison MediPharma Company Details

Table 139. Hutchison MediPharma Business Overview

Table 140. Hutchison MediPharma FGF-2 Inhibitors Product

Table 141. Hutchison MediPharma Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 142. Hutchison MediPharma Recent Developments

Table 143. Novartis Company Details

Table 144. Novartis Business Overview

Table 145. Novartis FGF-2 Inhibitors Product

Table 146. Novartis Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 147. Novartis Recent Developments

Table 148. Principia Biopharma Company Details

Table 149. Principia Biopharma Business Overview

Table 150. Principia Biopharma FGF-2 Inhibitors Product

Table 151. Principia Biopharma Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 152. Principia Biopharma Recent Developments

Table 153. Vichem Chemie Research Company Details

Table 154. Vichem Chemie Research Business Overview

Table 155. Vichem Chemie Research FGF-2 Inhibitors Product

Table 156. Vichem Chemie Research Revenue in FGF-2 Inhibitors Business (2019-2024) & (US$ Million)

Table 157. Vichem Chemie Research Recent Developments

Table 158. Research Programs/Design for This Report

Table 159. Key Data Information from Secondary Sources

Table 160. Key Data Information from Primary Sources

List of Figures

Figure 1. Global FGF-2 Inhibitors Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global FGF-2 Inhibitors Market Share by Type: 2023 VS 2030

Figure 3. ASP-5878 Features

Figure 4. AZD-4547 Features

Figure 5. BAY-1163877 Features

Figure 6. CPL-043 Features

Figure 7. Debio-1347 Features

Figure 8. EDP-317 Features

Figure 9. Others Features

Figure 10. Global FGF-2 Inhibitors Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 11. Global FGF-2 Inhibitors Market Share by Application: 2023 VS 2030

Figure 12. Clinic Case Studies

Figure 13. Hospital Case Studies

Figure 14. Others Case Studies

Figure 15. FGF-2 Inhibitors Report Years Considered

Figure 16. Global FGF-2 Inhibitors Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global FGF-2 Inhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global FGF-2 Inhibitors Market Share by Region: 2023 VS 2030

Figure 19. Global FGF-2 Inhibitors Market Share by Players in 2023

Figure 20. Global Top FGF-2 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in FGF-2 Inhibitors as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by FGF-2 Inhibitors Revenue in 2023

Figure 22. North America FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America FGF-2 Inhibitors Market Share by Type (2019-2030)

Figure 24. North America FGF-2 Inhibitors Market Share by Application (2019-2030)

Figure 25. North America FGF-2 Inhibitors Market Share by Country (2019-2030)

Figure 26. United States FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Canada FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe FGF-2 Inhibitors Market Size YoY (2019-2030) & (US$ Million)

Figure 29. Europe FGF-2 Inhibitors Market Share by Type (2019-2030)

Figure 30. Europe FGF-2 Inhibitors Market Share by Application (2019-2030)

Figure 31. Europe FGF-2 Inhibitors Market Share by Country (2019-2030)

Figure 32. Germany FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. France FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. U.K. FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Italy FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Russia FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Nordic Countries FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. China FGF-2 Inhibitors Market Size YoY (2019-2030) & (US$ Million)

Figure 39. China FGF-2 Inhibitors Market Share by Type (2019-2030)

Figure 40. China FGF-2 Inhibitors Market Share by Application (2019-2030)

Figure 41. Asia FGF-2 Inhibitors Market Size YoY (2019-2030) & (US$ Million)

Figure 42. Asia FGF-2 Inhibitors Market Share by Type (2019-2030)

Figure 43. Asia FGF-2 Inhibitors Market Share by Application (2019-2030)

Figure 44. Asia FGF-2 Inhibitors Market Share by Region (2019-2030)

Figure 45. Japan FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. South Korea FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. China Taiwan FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Southeast Asia FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. India FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Australia FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Size YoY (2019-2030) & (US$ Million)

Figure 52. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Share by Type (2019-2030)

Figure 53. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Share by Application (2019-2030)

Figure 54. Middle East, Africa, and Latin America FGF-2 Inhibitors Market Share by Country (2019-2030)

Figure 55. Brazil FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Mexico FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Turkey FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Saudi Arabia FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 59. Israel FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 60. GCC Countries FGF-2 Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 61. Advenchen Laboratories Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 62. Amgen Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 63. ArQule Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 64. Santa Cruz Biotechnology Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 65. AstraZeneca Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 66. AVEO Pharmaceuticals Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 67. Batu Biologics Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 68. Boehringer Ingelheim Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 69. Bristol-Myers Squibb Company Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 70. Celon Pharma Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 71. Debiopharm International Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 72. Eddingpharm Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 73. Eisai Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 74. Eli Lilly and Company Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 75. Hutchison MediPharma Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 76. Novartis Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 77. Principia Biopharma Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 78. Vichem Chemie Research Revenue Growth Rate in FGF-2 Inhibitors Business (2019-2024)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions